

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported)

March 11, 2021



option care health®

**OPTION CARE HEALTH, INC.**

(Exact name of registrant as specified in its charter)

Delaware

(State or other jurisdiction of incorporation)

001-11993

(Commission File Number)

05-0489664

(IRS Employer Identification Number)

3000 Lakeside Dr. Suite 300N, Bannockburn, IL 60015

(Address of principal executive offices)

(312) 940-2443

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Securities registered pursuant to Section 12(b) of the Act:

Title of each Class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, \$0.0001 par value per share	OPCH	Nasdaq Global Select Market



---

**Item 2.02. Results of Operations and Financial Condition.**

On March 11, 2021, Option Care Health, Inc. issued a press release reporting its fourth quarter and full-year 2020 financial results. A copy of the press release is furnished with this Form 8-K and attached hereto as Exhibit 99.1.

The press release includes certain non-GAAP financial measures described therein. Reconciliation between any non-GAAP financial measures presented and the most directly comparable GAAP financial measures is also provided.

The information in this Form 8-K and the Exhibit attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.

**Item 9.01. Financial Statements and Exhibits**

(d) Exhibits

<u>Exhibit No.</u>	<u>Description</u>
<a href="#">99.1</a>	<a href="#">Press release dated March 11, 2021</a>

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**Option Care Health, Inc.**

Date: March 11, 2021

By: /s/ Michael Shapiro  
Michael Shapiro  
Chief Financial Officer



option care health®

**OPTION CARE HEALTH ANNOUNCES FINANCIAL RESULTS FOR FOURTH QUARTER AND FULL YEAR 2020 AND PROVIDES GUIDANCE FOR FULL YEAR 2021**

**BANNOCKBURN, IL., March 11, 2021** - Option Care Health, Inc. (the “Company” or “Option Care Health”) (Nasdaq: OPCH), the nation’s largest independent provider of home and alternate site infusion services, announced today financial results for the fourth quarter and full year ended December 31, 2020.

Given the merger between Option Care Enterprises, Inc. (“Option Care”) and BioScrip, Inc. (“BioScrip”) to form Option Care Health on August 6, 2019, comparisons to historical periods are relative to legacy Option Care only and incorporate BioScrip results from August 6, 2019 prospectively.

**Fourth Quarter 2020 Financial Highlights**

- Net revenue of \$804.7 million, up 11.6% compared to \$720.8 million in the fourth quarter of 2019
- Gross profit of \$183.8 million, or 22.8% of revenue, up 4.6% compared to \$175.6 million, or 24.4% of revenue, in the fourth quarter of 2019
- Net income of \$17.8 million, or \$0.10 earnings per share, compared to net loss of \$15.8 million, or \$0.09 loss per share, in the fourth quarter of 2019
- Adjusted EBITDA of \$67.7 million, up 27.7% compared to \$53.0 million in the fourth quarter of 2019
- Cash flow from operations of \$25.7 million, up 12.1% compared to \$22.9 million in the fourth quarter of 2019
- Cash balances of \$99.3 million at the end of the fourth quarter and no outstanding borrowings on the Company’s \$175.0 million revolver

**Full Year 2020 Financial Highlights**

- Net revenue of \$3,032.6 million, up 31.3% compared to \$2,310.4 million in the full year 2019
- Gross profit of \$682.3 million, or 22.5% of revenue, up 33.0% compared to \$513.0 million, or 22.2% of revenue, in full year 2019
- Net loss of \$8.1 million, or \$0.04 loss per share, compared to net loss of \$75.9 million, or \$0.49 loss per share, in full year 2019
- Adjusted EBITDA of \$221.7 million, up 69.5% compared to \$130.8 million in full year 2019
- Cash flow from operations of \$127.4 million, up 222.8% compared to \$39.5 million in full year 2019

John C. Rademacher, Chief Executive Officer, commented, “I am incredibly proud of the effort and execution by the Option Care Health team in the face of an exceptionally challenging year. In addition to delivering strong financial results, the team continued to focus on integration efforts and laying the groundwork for future growth while always remaining focused on the thousands of patients relying on us for critical therapy every single day.”

### **Full Year 2021 Financial Guidance**

For the full year 2021, Option Care Health expects to deliver the following financial results:

- Net revenue of \$3.20 billion to \$3.25 billion
- Adjusted EBITDA of \$245.0 million to \$258.0 million
- Cash flow from operations of at least \$140.0 million
- Net debt to Adjusted EBITDA leverage ratio at December 31, 2021 below 4.0x

### **Conference Call**

The conference call can be accessed by dialing (866) 360-3136 for U.S. participants or (602) 563-8603 for international participants, and referencing conference ID 1899337; or via a live audio webcast that will be available online at [investors.optioncarehealth.com](https://investors.optioncarehealth.com). A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call, at the same web link, and will remain available for approximately 90 days.

### **About Option Care Health**

Option Care Health is the nation’s largest independent provider of home and alternate site infusion services. With over 5,000 teammates, including approximately 2,900 clinicians, we work compassionately to elevate standards of care for patients with acute and chronic conditions in all 50 states. Through our clinical leadership, expertise and national scale, Option Care Health is reimagining the infusion care experience for patients, customers and teammates. To learn more, please visit our website at [OptionCareHealth.com](https://OptionCareHealth.com).

### **Investor Contacts**

Mike Shapiro  
Chief Financial Officer  
T: (312) 940-2538  
[mike.shapiro@optioncare.com](mailto:mike.shapiro@optioncare.com)

Bob East, Asher Dewhurst, Jordan Kohnstam  
Westwicke  
T: (413) 213-0500  
[optioncarehealth@westwicke.com](mailto:optioncarehealth@westwicke.com)

## **Forward-Looking Statements - Safe Harbor**

This press release may contain “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “anticipate,” “intend,” “plan,” “believe,” “project,” “estimate,” “expect,” “may,” “should,” “will” and similar references to future periods. Examples of forward-looking statements include, among others, statements we may make regarding future revenues, future earnings, regulatory developments, market developments, new products and growth strategies, integration activities and the effects of any of the foregoing on our future results of operations or financial conditions.

Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: (i) changes in laws and regulations applicable to our business model; (ii) changes in market conditions and receptivity to our services and offerings; (iii) results of litigation; and (iv) the loss of one or more key payers. For a detailed discussion of the risk factors that could affect our actual results, please refer to the risk factors identified in our SEC reports as filed with the SEC.

Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

## **Note Regarding Use of Non-GAAP Financial Measures**

In addition to reporting financial information in accordance with generally accepted accounting principles (GAAP), the Company is also reporting Adjusted EBITDA, which is a non-GAAP financial measure. Adjusted EBITDA is not a measurement of financial performance under GAAP and should not be used in isolation or as a substitute or alternative to net income, operating income or any other performance measure derived in accordance with GAAP, or as a substitute or alternative to cash flow from operating activities or a measure of the Company’s liquidity. In addition, the Company’s definition of Adjusted EBITDA may not be comparable to similarly titled non-GAAP financial measures reported by other companies. Adjusted EBITDA, as defined by the Company, represents net income before net interest expense, income tax expense, depreciation and amortization, stock-based compensation expense, and restructuring, integration and other expenses. As part of restructuring, integration and other expenses, the Company may incur significant charges such as the write down of certain long-lived assets, temporary redundant expenses, professional fees, potential retention and severance costs and potential accelerated payments or termination costs for certain of its contractual obligations. Management believes that Adjusted EBITDA provides useful supplemental information regarding the performance of Option Care Health’s business operations and facilitates comparisons to the Company’s historical operating results. For a full reconciliation of Adjusted EBITDA to the most comparable GAAP financial measure, please see the attachment to this earnings release.

**OPTION CARE HEALTH, INC.**  
**CONDENSED CONSOLIDATED BALANCE SHEETS**  
**(IN THOUSANDS)**

	December 31,	
	2020	2019
<b>ASSETS</b>		
<b>CURRENT ASSETS:</b>		
Cash and cash equivalents	\$ 99,265	\$ 67,056
Accounts receivable, net	328,340	324,416
Inventories	158,601	115,876
Prepaid expenses and other current assets	70,806	51,306
<b>Total current assets</b>	<b>657,012</b>	<b>558,654</b>
<b>NONCURRENT ASSETS:</b>		
Property and equipment, net	121,149	133,198
Intangible assets, net	351,052	385,910
Goodwill	1,428,610	1,425,542
Other noncurrent assets	89,616	86,243
<b>Total noncurrent assets</b>	<b>1,990,427</b>	<b>2,030,893</b>
<b>TOTAL ASSETS</b>	<b>\$ 2,647,439</b>	<b>\$ 2,589,547</b>
<b>LIABILITIES AND STOCKHOLDERS' EQUITY</b>		
<b>CURRENT LIABILITIES:</b>		
Accounts payable	\$ 282,913	\$ 221,060
Other current liabilities	151,110	108,944
<b>Total current liabilities</b>	<b>434,023</b>	<b>330,004</b>
<b>NONCURRENT LIABILITIES:</b>		
Long-term debt, net of discount, deferred financing costs and current portion	1,115,103	1,277,246
Other noncurrent liabilities	82,589	75,470
<b>Total noncurrent liabilities</b>	<b>1,197,692</b>	<b>1,352,716</b>
<b>Total liabilities</b>	<b>1,631,715</b>	<b>1,682,720</b>
<b>STOCKHOLDERS' EQUITY</b>	<b>1,015,724</b>	<b>906,827</b>
<b>TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY</b>	<b>\$ 2,647,439</b>	<b>\$ 2,589,547</b>

**OPTION CARE HEALTH, INC.**  
**CONDENSED CONSOLIDATED STATEMENTS OF EARNINGS**  
**(IN THOUSANDS, EXCEPT PER SHARE AMOUNTS)**

	Three Months Ended December 31,		Year Ended December 31,	
	2020	2019	2020	2019
NET REVENUE	\$ 804,713	\$ 720,779	\$ 3,032,610	\$ 2,310,417
COST OF REVENUE	620,951	545,137	2,350,346	1,797,418
GROSS PROFIT	183,762	175,642	682,264	512,999
<b>OPERATING COSTS AND EXPENSES:</b>				
Selling, general and administrative expenses	123,001	144,121	500,199	459,628
Depreciation and amortization expense	16,418	17,548	71,310	53,690
Total operating expenses	139,419	161,669	571,509	513,318
OPERATING INCOME (LOSS)	44,343	13,973	110,755	(319)
<b>OTHER INCOME (EXPENSE):</b>				
Interest expense, net	(23,668)	(29,607)	(107,770)	(73,724)
Other, net	(2,270)	818	(8,228)	(4,151)
Total other expense	(25,938)	(28,789)	(115,998)	(77,875)
INCOME (LOSS) BEFORE INCOME TAXES	18,405	(14,816)	(5,243)	(78,194)
INCOME TAX EXPENSE (BENEFIT)	566	995	2,833	(2,274)
NET INCOME (LOSS)	\$ 17,839	\$ (15,811)	\$ (8,076)	\$ (75,920)
Earnings (loss) per share, basic and diluted	\$ 0.10	\$ (0.09)	\$ (0.04)	\$ (0.49)

**OPTION CARE HEALTH, INC.**  
**CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS**  
**(IN THOUSANDS)**

	<b>Year Ended December 31,</b>	
	<b>2020</b>	<b>2019</b>
<b>CASH FLOWS FROM OPERATING ACTIVITIES:</b>		
Net loss	(8,076)	(75,920)
Adjustments to reconcile net loss to net cash provided by operations:		
Depreciation and amortization expense	77,896	57,869
Paid-in-kind interest capitalized as principal	7,525	12,256
Other non-cash adjustments	42,917	29,236
Changes in operating assets and liabilities:		
Accounts receivable, net	(3,924)	82,285
Inventories	(42,725)	(12,853)
Accounts payable	59,215	(30,856)
Other	(5,436)	(22,550)
Net cash provided by operating activities	<u>127,392</u>	<u>39,467</u>
<b>CASH FLOWS FROM INVESTING ACTIVITIES:</b>		
Acquisition of property and equipment	(26,875)	(28,292)
Other investing cash flows	541	636
Business acquisitions, net of cash acquired	—	(700,170)
Net cash used in investing activities	<u>(26,334)</u>	<u>(727,826)</u>
<b>CASH FLOWS FROM FINANCING ACTIVITIES:</b>		
Proceeds from debt	—	981,050
Retirement of debt obligations	(174,000)	(226,738)
Net proceeds from issuance of common stock	118,934	—
Deferred financing costs	(149)	(30,022)
Other financing cash flows	(13,634)	(5,266)
Net cash (used in) provided by financing activities	<u>(68,849)</u>	<u>719,024</u>
NET INCREASE IN CASH AND CASH EQUIVALENTS	32,209	30,665
Cash and cash equivalents - beginning of the period	67,056	36,391
CASH AND CASH EQUIVALENTS - END OF PERIOD	<u>99,265</u>	<u>67,056</u>

**OPTION CARE HEALTH, INC.**  
**QUARTERLY RECONCILIATION BETWEEN GAAP AND NON-GAAP MEASURES**  
**(IN THOUSANDS)**  
**(UNAUDITED)**

	Three Months Ended December 31,		Year Ended December 31,	
	2020	2019	2020	2019
Consolidated net income (loss)	\$ 17,839	\$ (15,811)	\$ (8,076)	\$ (75,920)
Interest expense, net	23,668	29,607	107,770	73,724
Income tax expense (benefit)	566	995	2,833	(2,274)
Depreciation and amortization expense	17,842	18,872	77,896	57,869
Consolidated EBITDA	59,915	33,663	180,423	53,399
<b>EBITDA adjustments</b>				
Accounting principle changes and non-cash charges	—	—	—	8,535
Stock-based incentive compensation	332	272	2,920	4,170
Loss on extinguishment of debt	3,196	—	11,545	5,469
Restructuring, acquisition, integration and other	4,208	19,027	26,788	59,178
Consolidated adjusted EBITDA	\$ 67,651	\$ 52,962	\$ 221,676	\$ 130,751